Lorlagen(Lorlatinib)100mg

0.00$

Lorlagen is a pharmaceutical drug presented in 100mg tablet form, comprising Lorlatinib as its primary compound. Lorlatinib, functioning as a tyrosine kinase inhibitor, is employed to treat particular cancer varieties, notably non-small cell lung cancer (NSCLC) bearing distinctive mutations like ALK or ROS1 gene alterations. Its mechanism entails inhibiting the aberrant activity of these mutated proteins, which play a crucial role in the proliferation and dissemination of cancerous cells. Healthcare providers commonly include Lorlagen in the treatment regimen for suitable patients diagnosed with these specific cancer types.

Add to wishlist
Share

    Indication:
    Lorlagen, containing 100mg of Lorlatinib in tablet form, is prescribed for treating specific cancer types, notably non-small cell lung cancer (NSCLC) harboring ALK or ROS1 gene mutations.

    Pharmacology:
    Lorlatinib, classified as a tyrosine kinase inhibitor, operates by impeding the function of mutated proteins like ALK or ROS1, pivotal for cancer cell proliferation and dissemination. Lorlatinib’s action helps hinder the advancement of cancer.

    Dosage and Administration:
    The recommended dosage of Lorlagen is typically administered orally, with or without food, under the guidance of a healthcare provider. Specific dosing and treatment duration depend on individual patient characteristics and the cancer stage being addressed.

    Interaction:
    Lorlagen may interact with various medications, including other tyrosine kinase inhibitors and drugs metabolized by cytochrome P450 enzymes. Patients should inform their healthcare provider about all medications, supplements, and herbal products they are using to prevent potential interactions.

    Side Effects:
    Common side effects of Lorlagen may encompass fatigue, nausea, diarrhea, alterations in taste perception, and peripheral edema. More severe adverse effects like hepatotoxicity, interstitial lung disease, and neurological complications can also manifest. Patients should promptly report any severe or persistent side effects to their healthcare provider.

    Precautions and Warnings:
    Patients undergoing treatment with Lorlagen should undergo close monitoring for potential adverse reactions, especially liver and pulmonary function tests. Usage of Lorlagen during pregnancy may pose fetal harm, warranting contraception for both genders during treatment and a specified period afterward. Breastfeeding is not recommended while on Lorlagen.

    Overdose Effects:
    In instances of Lorlagen overdose, patients may experience intensified adverse effects such as gastrointestinal symptoms, hepatotoxicity, and neurological issues. Overdose management typically involves supportive care and vigilance for complications. Immediate medical attention is crucial if an overdose is suspected.

    Product Name

    Lorlagen

    Generic Name

    Lorlatinib

    Formulation

    Capsule

    Available Pack Size

    30's

    Available Strength

    100mg